In short
This article explores an innovative clinical trial investigating the use of CD1C+/CD141+ Myeloid Dendritic Cells isolated from peripheral blood mononuclear cells in combination with other immunotherapy drugs for the treatment of recurrent glioblastoma. The study aims to evaluate the safety and effectiveness of this novel approach in patients who have undergone surgery for this aggressive brain cancer.
At a glance
- Study Type
- Phase I clinical trial
- Condition
- Recurrent glioblastoma
- Main Treatment
- Autologous CD1C+/CD141+ myeloid dendritic cells, nivolumab, and ipilimumab
- Administration Routes
- Intratumoral, intracavitary, and intravenous
- Primary Outcome
- Incidence of treatment-related severe adverse events
- Secondary Outcomes
- Objective response rate (ORR), progression-free survival (PFS), overall survival (OS)
- Key Eligibility Criteria
- Adults with recurrent glioblastoma, previous standard treatment, adequate organ function
- Exclusion Criteria
- Active autoimmune disease, recent use of immunosuppressive medications, other severe medical conditions
What are CD1C+/CD141+ Myeloid Dendritic Cells?
CD1C+/CD141+ Myeloid Dendritic Cells, also known as BDCA-1+/BDCA-3+ myeloid dendritic cells, are a type of immune cell isolated from a patient's own blood. These cells are part of a new and innovative treatment approach called cell therapy. In this treatment, these specific dendritic cells are extracted from the patient's blood, processed, and then used as a medication.
Medical Condition Treated
This treatment is being studied for patients with recurrent glioblastoma. Glioblastoma is a type of aggressive brain cancer that often returns after initial treatment. When it comes back, it's called recurrent glioblastoma.
How the Treatment Works
The treatment involves several steps:
- Collecting the patient's blood cells through a process called leukapheresis
- Isolating and processing the specific CD1C+/CD141+ myeloid dendritic cells
- Injecting these processed cells directly into the brain tumor or the area where the tumor was removed
- Combining this cell therapy with other cancer treatments called nivolumab and ipilimumab
The goal is to stimulate the patient's immune system to fight the cancer cells more effectively.
Clinical Trial Details
This treatment is currently being studied in a Phase I clinical trial. The main objectives of the trial are:
- To assess the safety of injecting these dendritic cells along with nivolumab and ipilimumab
- To evaluate how well this combination therapy works against the tumor
The trial is also looking at how long patients survive without their cancer getting worse (progression-free survival) and overall survival rates.
Eligibility Criteria
To participate in this clinical trial, patients must meet certain criteria. Some key requirements include:
- Being 18 years or older
- Having a confirmed diagnosis of recurrent glioblastoma
- Having completed previous standard treatments (surgery, radiation, and chemotherapy with temozolomide)
- Having adequate organ function and overall health status
- Not having certain autoimmune diseases or other cancers
There are additional specific medical criteria that doctors will evaluate to determine if a patient is eligible for the trial.
Potential Benefits and Risks
Potential benefits of this treatment may include:
- A new option for treating recurrent glioblastoma, which can be difficult to treat
- Possible improvement in survival time or quality of life
- Contributing to the advancement of cancer research
However, as with any experimental treatment, there are also potential risks:
- Side effects from the cell therapy or the other medications used
- The possibility that the treatment may not be effective
- Risks associated with the surgical procedures needed to deliver the treatment
It's important for patients to discuss these potential benefits and risks thoroughly with their healthcare team before deciding to participate in the clinical trial.